# EDGAR Filing Document

**Accession Number:** 0001631574
**File Stem:** 0001193125-25-314736
**Filing Date:** 2025-12
**Character Count:** 9269
**Document Hash:** c1dbd945dfa96b35cdb5146b45d9c30a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-314736.hdr.sgml**: 20251210

**ACCESSION NUMBER**: 0001193125-25-314736

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251208

**FILED AS OF DATE**: 20251210

**DATE AS OF CHANGE**: 20251210

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Moran Kyle
- **CENTRAL INDEX KEY:** 0001657765

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37627
- **FILM NUMBER:** 251563353

**MAIL ADDRESS:**
- **STREET 1:** C/O WAVE LIFE SCIENCES LTD.
- **STREET 2:** 733 CONCORD AVE.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02138
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Wave Life Sciences Ltd.
- **CENTRAL INDEX KEY:** 0001631574
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** U0
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 7 STRAITS VIEW
- **STREET 2:** #12-00, MARINA ONE EAST TOWER
- **CITY:** SINGAPORE
- **STATE:** U0
- **ZIP:** 018936
- **BUSINESS PHONE:** 617-949-2900

**MAIL ADDRESS:**
- **STREET 1:** 733 CONCORD AVENUE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02138

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WAVE Life Sciences Ltd.
- **DATE OF NAME CHANGE:** 20170516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Wave Life Sciences Ltd.
- **DATE OF NAME CHANGE:** 20151106

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Wave Life Sciences LTD.
- **DATE OF NAME CHANGE:** 20151106

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Moran Kyle<br><sub>(Last) (First) (Middle)</sub><br>C/O WAVE LIFE SCIENCES LTD.,<br>733 CONCORD AVE.<br><sub>(Street)</sub><br>CAMBRIDGE, MA 02138<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-08 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Financial Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Wave Life Sciences Ltd. [ WVE ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2025-12-08 |  | M<sup>(1)</sup> |  | 60000 | A | $2.83 | 149218 | D |  |
| Ordinary Shares | 2025-12-08 |  | S<sup>(1)</sup> |  | 60000 | D | $13.20 | 89218 | D |  |
| Ordinary Shares | 2025-12-08 |  | M<sup>(1)</sup> |  | 100000 | A | $3.14 | 189218 | D |  |
| Ordinary Shares | 2025-12-08 |  | S<sup>(1)</sup> |  | 50000 | D | 15.00<sup>(4)</sup> | 139218 | D |  |
| Ordinary Shares | 2025-12-08 |  | S<sup>(1)</sup> |  | 50000 | D | $13.20 | 89218 | D |  |
| Ordinary Shares | 2025-12-08 |  | M<sup>(1)</sup> |  | 50000 | A | $4.75 | 139218 | D |  |
| Ordinary Shares | 2025-12-08 |  | S<sup>(1)</sup> |  | 50000 | D | $18.00 | 89218 | D |  |
| Ordinary Shares | 2025-12-09 |  | M<sup>(1)</sup> |  | 36000 | A | $8.17 | 125218 | D |  |
| Ordinary Shares | 2025-12-09 |  | S<sup>(1)</sup> |  | 36.000 | D | 20.25<sup>(6)</sup> | 89218 | D |  |
| Ordinary Shares | 2025-12-09 |  | M<sup>(1)</sup> |  | 50000 | A | $10.48 | 139218 | D |  |
| Ordinary Shares | 2025-12-09 |  | S<sup>(1)</sup> |  | 50000 | D | 20.025<sup>(6)</sup> | 90365<sup>(7)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Share Option (right to buy) | $2.83 | 2025-12-08 |  | A |  |  | 60000 | <sup>(2)</sup> | 2032-07-25 | Ordinary Shares | 60000 | $0 | 0 | D |  |
| Share Option (right to buy) | $3.14 | 2025-12-08 |  | A |  |  | 100000 | <sup>(3)</sup> | 2032-01-01 | Ordinary Shares | 100000 | $0 | 75000 | D |  |
| Share Option (right to buy) | $4.75 | 2025-12-08 |  | A |  |  | 50000 | <sup>(5)</sup> | 2033-02-17 | Ordinary Shares | 50000 | $0 | 222700 | D |  |
| Share Option (right to buy) | $8.17 | 2025-12-09 |  | A |  |  | 36000 | <sup>(2)</sup> | 2030-03-03 | Ordinary Shares | 36000 | $0 | 0 | D |  |
| Share Option (right to buy) | $10.48 | 2025-12-09 |  | A |  |  | 50000 | <sup>(2)</sup> | 2031-02-01 | Ordinary Shares | 50000 | $0 | 0 | D |  |

---

### Footnotes:

(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.

(2) These share options are fully vested.

(3) The share option represented a right to purchase a total of 175,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026.

(4) The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.045 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

(5) The share option represented a right to purchase a total of 272,200 ordinary shares that vest as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.

(6) The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $20.00 to $20.22 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

(7) Includes 1,147 ordinary shares acquired on July 14, 2025, under the issuer's 2019 Employee Share Purchase Plan.

**Signature:** /s/ Kyle Moran  
**Date:** 2025-12-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**